Pharming Group (ENXTAM:PHARM) - Prezzo delle azioni, notizie e analisi

PHARM Panoramica delle azioni

PHARM analisi fondamentale
Punteggio fiocco di neve
Valutazione	6/6
Crescita futura	4/6
Prestazioni passate	0/6
Salute finanziaria	5/6
Dividendi	0/6

Premi

Negoziato a 91.4% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 73.16% all'anno

Negoziato a un buon valore rispetto ai pari e al settore

Gli analisti concordano sul fatto che il prezzo delle azioni salirà di 159%

Analisi del rischio

Prezzo delle azioni volatile negli ultimi 3 mesi

Pharming Group N.V. Concorrenti

Galapagos

ENXTAM:GLPG

€1.6b

HLB TherapeuticsLtd

KOSDAQ:A115450

₩838.7b

Rigel Pharmaceuticals

NasdaqGS:RIGL

US$428.2m

Medy-Tox

KOSDAQ:A086900

₩856.2b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Pharming Group
Prezzi storici delle azioni
Prezzo attuale dell'azione	€0.69
Massimo di 52 settimane	€1.22
Minimo di 52 settimane	€0.65
Beta	0.81
1Variazione di 1 mese	-17.61%
Variazione a 3 mesi	-4.47%
Variazione di 1 anno	-34.37%
3Variazione a 3 anni	-8.29%
Variazione a 5 anni	-49.71%
Variazione dall'IPO	-99.26%

Notizie e aggiornamenti recenti

Recent updates

Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price

Feb 14

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Nov 11

Pharming Group N.V. (AMS:PHARM) Shares Could Be 49% Below Their Intrinsic Value Estimate

Aug 23

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Jun 20

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Mar 16

Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 41% Above Its Share Price

Feb 17

We Think Pharming Group (AMS:PHARM) Can Manage Its Debt With Ease

Dec 08

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Aug 05

Pharming Group N.V. Just Missed EPS By 56%: Here's What Analysts Think Will Happen Next

Mar 21

These Analysts Think Pharming Group N.V.'s (AMS:PHARM) Sales Are Under Threat

Mar 19

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Feb 20

Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 40% Above Its Share Price

Oct 29

Pharming Group (AMS:PHARM) Seems To Use Debt Quite Sensibly

Jun 03

Increases to CEO Compensation Might Be Put On Hold For Now at Pharming Group N.V. (AMS:PHARM)

May 12

Rendimenti per gli azionisti

	PHARM	NL Biotechs	NL Mercato
7D	-5.5%	-5.0%	-2.5%
1Y	-34.4%	2.3%	6.4%

Ritorno vs Industria: PHARM ha avuto una performance inferiore rispetto al Dutch Biotechs che ha registrato un rendimento 2.3 % nell'ultimo anno.

Rendimento vs Mercato: PHARM ha avuto una performance inferiore al mercato Dutch che ha registrato un rendimento 6.4 % nell'ultimo anno.

Volatilità dei prezzi

Is PHARM's price volatile compared to industry and market?
PHARM volatility
PHARM Average Weekly Movement	6.8%
Biotechs Industry Average Movement	7.9%
Market Average Movement	4.0%
10% most volatile stocks in NL Market	7.5%
10% least volatile stocks in NL Market	2.2%

Prezzo delle azioni stabile: Il prezzo delle azioni di PHARM è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 7% ) di PHARM è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni Dutch.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1988	382	Simon de Vries	www.pharming.com

Pharming Group N.V., azienda biofarmaceutica, sviluppa e commercializza terapie sostitutive delle proteine e farmaci di precisione per il trattamento di malattie rare negli Stati Uniti, in Europa e a livello internazionale. L'azienda offre RUCONEST, un inibitore ricombinante della C1 esterasi per il trattamento degli attacchi acuti in pazienti adulti e adolescenti affetti da angioedema ereditario acuto (HAE); e Joenja (leniolisib), un inibitore PI3K? orale a piccola molecola per il trattamento della sindrome delta fosfoinositide 3-chinasi attivata.

Pharming Group N.V. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Pharming Group con la sua capitalizzazione di mercato?
PHARM statistiche fondamentali
Capitalizzazione di mercato	€471.46m
Guadagni(TTM)	-€17.00m
Ricavi(TTM)	€272.60m

1.7x

Rapporto P/S

-27.7x

Rapporto P/E

PHARM è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
PHARM Conto economico (TTM)
Ricavi	US$285.75m
Costo del fatturato	US$30.30m
Profitto lordo	US$255.44m
Altre spese	US$273.26m
Guadagni	-US$17.82m

Ultimi guadagni dichiarati

Sep 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-0.026
Margine lordo	89.39%
Margine di profitto netto	-6.24%
Rapporto debito/patrimonio netto	42.3%

Come si è comportato PHARM nel lungo periodo?

Vedi performance storica e confronto

PHARM Panoramica delle azioni

Premi

Analisi del rischio

Pharming Group N.V. Concorrenti

ENXTAM:GLPG

€1.6b

KOSDAQ:A115450

₩838.7b

NasdaqGS:RIGL

US$428.2m

KOSDAQ:A086900

₩856.2b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Consensus estimates of losses per share improve by 14%

Third quarter 2024 earnings released: US$0.002 loss per share (vs US$0.005 profit in 3Q 2023)

Pharming Group Announces Start of Phase II Clinical Trial of Leniolisib for Primary Immunodeficiencies (PIDs) with Immune Dysregulation

New minor risk - Share price stability

Price target decreased by 7.8% to €1.78

New minor risk - Share price stability

Recent updates

Consensus estimates of losses per share improve by 14%

Third quarter 2024 earnings released: US$0.002 loss per share (vs US$0.005 profit in 3Q 2023)

Pharming Group Announces Start of Phase II Clinical Trial of Leniolisib for Primary Immunodeficiencies (PIDs) with Immune Dysregulation

New minor risk - Share price stability

Price target decreased by 7.8% to €1.78

New minor risk - Share price stability

Second quarter 2024 earnings released: US$0.002 loss per share (vs US$0.002 profit in 2Q 2023)

Insufficient new directors

Pharming Group N.V. Provides Update on Ongoing Regulatory Review of Leniolisib for the Treatment of Apds in the European Union

Pharming Group N.V. Provides Revenue Guidance for 2024

First quarter 2024 earnings released: US$0.019 loss per share (vs US$0.019 loss in 1Q 2023)

Pharming Group N.V. announced that it expects to receive €100 million in funding

Price target increased by 11% to €2.00

Full year 2023 earnings released: US$0.015 loss per share (vs US$0.021 profit in FY 2022)

Pharming Group N.V. to Report Q2, 2024 Results on Aug 01, 2024

Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price

Consensus estimates of losses per share improve by 31%

Pharming Group N.V. to Report Q4, 2023 Results on Mar 14, 2024

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Consensus EPS estimates upgraded to US$0.014 loss, revenue downgraded

Consensus estimates of losses per share improve by 34%

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: EPS: US$0.005 (vs US$0.014 in 3Q 2022)

Pharming Group N.V. Appoints Richard Peters as Non-Executive Director

Pharming Group N.V. (AMS:PHARM) Shares Could Be 49% Below Their Intrinsic Value Estimate

Consensus EPS estimates fall by 140%

Pharming Group N.V. Announces First Patient Enrolled in Phase Iii Clinical Trial of Leniolisib for the Treatment of Apds in Japan

First half 2023 earnings released: US$0.017 loss per share (vs US$0.03 profit in 1H 2022)

Pharming Group N.V. Appoints Alexander Breidenbach as Chief Business Officer

Now 20% undervalued

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Pharming Group N.V. Approves the Proposal to Reappoint Paul Sekhri, Chair of the Board, as Non-Executive Director for A Period of One Year Who Will Resign from the Board Upon Appointment of His Successor

Investor sentiment improves as stock rises 15%

Price target increased by 8.9% to €1.83

Investor sentiment improves as stock rises 18%

Full year 2022 earnings released: EPS: US$0.021 (vs US$0.025 in FY 2021)

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Pharming Group N.V. Provides Update on EMA Regulatory Review of Leniolisib for Apds in Europe

Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 41% Above Its Share Price

Now 20% undervalued

Now 20% undervalued

Investor sentiment improved over the past week

Pharming Group N.V. Announces Positive Interim Analysis Data from Open-Label Extension Study of Leniolisib in Presentation At the 64Th American Society of Hematology (ASH) Annual Meeting and Exposition

Pharming Group N.V. to Report Fiscal Year 2022 Results on Mar 16, 2023

Pharming Group N.V. Announces Positive Results of Phase 3 Clinical Trial of Investigational Drug Leniolisib

We Think Pharming Group (AMS:PHARM) Can Manage Its Debt With Ease

High number of new directors

Investor sentiment improved over the past week

Pharming Group N.V. Announces European Medicines Agency Validates its Marketing Authorisation Application Under Accelerated Assessment for Leniolisib

Third quarter 2022 earnings: EPS exceeds analyst expectations

Pharming Group N.V. Submits Marketing Authorisation Application to European Medicines Agency for Leniolisib

Price target increased to €13.52

Pharming Group N.V. Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib

Second quarter 2022 earnings released: EPS: US$0.025 (vs US$0.009 in 2Q 2021)

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Pharming Announces New ICD-10-CM Code for APDS, a Rare Primary Immunodeficiency

Pharming Group N.V. Receives Accelerated Assessment in Europe for Leniolisib for the Treatment of Rare Immunodeficiency, APDS

Consensus forecasts updated

First quarter 2022 earnings: EPS misses analyst expectations